Haemonetics Corporation (HAE)

Gross profit margin

		Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Gross profit	US$ in thousands	691,548	615,097	505,502	397,838	484,513
Revenue	US$ in thousands	2,594,610	2,323,320	985,896	860,363	972,079
Gross profit margin		26.65%	26.47%	51.27%	46.24%	49.84%

March 31, 2024 calculation

Gross profit margin = Gross profit ÷ Revenue
= $691,548K ÷ $2,594,610K
= 26.65%

Haemonetics Corporation's gross profit margin has shown fluctuating trends over the past five years. In the most recent fiscal year ending March 31, 2024, the gross profit margin was 26.65%, which represents a slight increase compared to the previous year's margin of 26.47%. However, it is notably lower than the margin reported in fiscal years 2022, 2021, and 2020, which were 51.27%, 46.24%, and 49.84%, respectively.

The significant drop in gross profit margin from fiscal year 2022 to 2023 may indicate challenges or changes in the company's cost structure or pricing strategy during that period. Although there was a slight improvement in the margin from 2023 to 2024, further analysis would be needed to understand the underlying factors contributing to this change.

Overall, the downward trend in gross profit margin over the past two years raises potential concerns related to the company's ability to maintain profitability and efficiency in its operations. Further investigation into the company's cost management, pricing dynamics, and overall business strategy would be necessary to assess the sustainability and competitiveness of Haemonetics Corporation's gross profit margin performance.